Summary:
A Phase III, Randomized, Placebo Controlled, Observer Blind, multi counrty study to demonstrate the efficacy of a single dose of GSK's RSVPreF3 OA investigational vaccine in adults aged 60 years and above.
Qualified Participants Must:
• Be at least 60 years old
• Never have been vaccinated for RSV before
Qualified Participants May Receive:
Access to doctore for length of trial; Compensation for your time and travel